首页> 外文期刊>Cardiology >Statin Lipophilicity and the Risk of Incident Heart Failure
【24h】

Statin Lipophilicity and the Risk of Incident Heart Failure

机译:他汀类药物嗜好性和事故心力衰竭的风险

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: To compare the risk of incident heart failure (HF) between initiators of hydrophilic and lipophilic statins. Methods: Using claims data for commercial health insurance program enrollees in the USA (2005–2014), we identified new initiators of hydrophilic or lipophilic statins. Follow-up for the primary outcome of incident HF began after a lag period of 1 year after statin initiation. The outcome was defined as 1 inpatient or 2 outpatient diagnosis codes for HF and the use of loop diuretics. Propensity scores (PS) were used to account for confounding. Hazard ratios (HR) for incident HF were computed separately for low and high-intensity statin users, and then pooled to provide dose-adjusted effect estimates. Results: A total of 7,820,204 patients met all our inclusion criteria for statin initiation (hydrophilic and lipophilic statins). Mean age was 58 years, 40% had hypertension, and 23% had diabetes mellitus. After PS matching, there were 691,584 patients in the low-intensity statin group and 807,370 patients in the high-intensity statin group. After a median follow-up of 725 days (IQR 500–1,153),there were 8,389 cases of incident HF (incidence rate 4.5/1,000 person years, 95% confidence interval [CI] 4.4–4.6). The unadjusted HR for the risk of HF was 0.77 (95% CI 0.76–0.79) and the pooled adjusted HR for incident HF after PS matching was 0.94 (95% CI 0.90–0.98) for hydrophilic versus lipophilic statins. The HR for incident HF was 1.06 (95% CI 1.00–1.12) for hydrophilic versus lipophilic statins for the low-intensity statin group and 0.82 (95% CI 0.78–0.87) for the high-intensity statin group. In subgroup analyses, a similar trend persisted for those younger and older than 65 years and when comparing rosuvastatin with atorvastatin. Conclusion: In this observational cohort study, hydrophilic statins were associated with a modest risk reduction in incident HF as compared to lipophilic statins. Future research replicating these findings in different populations is recommended.
机译:背景:比较亲水性和亲脂蛋白的引发剂之间的入射心力衰竭(HF)的风险。方法:在美国(2005-2014)中使用索赔数据进行商业健康保险计划登记,我们确定了亲水或亲肠他汀类药物的新引发剂。在他汀类药物启动后1年后的滞后期后,入射HF的主要结果的随访开始。结果定义为HF的1个内裤或2个门诊诊断码和环路利尿剂的使用。倾向分数(PS)被用来解释混杂。入射HF的危险比(HR)分别计算低强度和高强度的汀类药物,然后合并以提供剂量调整的效果估计。结果:共有7,820,204名患者满足了他汀类药物启动(亲水和亲脂蛋白)的所有纳入标准。平均年龄为58岁,40%的高血压高血压,23%有糖尿病。 PS匹配后,在低强度汀类药物组中有691,584名患者和807,370名高强度汀类药物组。经过725天的中位后续行动(IQR 500-1,153),事件8,389例事件(发病率4.5 / 1,000人,95%置信区间[CI] 4.4-4.6)。对于HF风险的不调整的HR为0.77(95%CI 0.76-0.79),并且PS匹配后的入射HR的合并的调节HR为304(95%CI 0.90-0.98),适用于亲水性与亲脂素。入射HF的HR为高强度汀类蛋白基团的亲水性与亲脂素组,对高强度汀类蛋白基团为1.06(95%CI 1.00-1.12)。在亚组分析中,对于那些年轻人和65岁的比较持续存在的相似趋势以及比较罗苏伐他汀与阿托伐他汀的比较。结论:在这种观察组合队列研究中,与亲肠毒素相比,亲水管毒素与入射HF的急性风险有关。建议使用未来研究这些发现的不同群体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号